Adverum Biotechnologies Inc (NAS:ADVM)
$ 4.8 -0.22 (-4.38%) Market Cap: 99.85 Mil Enterprise Value: 24.45 Mil PE Ratio: 0 PB Ratio: 0.69 GF Score: 34/100

Adverum Biotechnologies Inc Key Opinion Leader Discussion of OPTIC Phase 1 Clinical Trial Data of ADVM-022 in Wet AMD - Conference Call Transcript

Feb 09, 2020 / 03:00PM GMT
Leone D. Patterson
Adverum Biotechnologies, Inc. - President, CEO & Director

Okay, good morning, everyone. I'm Leone Patterson, the Chief Executive Officer of Adverum. And thank you, everybody, for joining me today, who's in the room. We also have people via webcast.

And we've got 90 minutes of time here for this meeting, and I'll make my comments brief because you obviously want to get to our panel discussion and obviously the presentation. Just some housekeeping: You can find the presentation that we'll have today on our website. And then also further -- there will be some forward-looking statements today, and these are disclaimers associated with those.

So getting to the agenda for the day, I wanted to just welcome our 3 prominent retinal specialists who are in the front of the room here: Dr. Khanani, Dr. Boyer and Dr. Kiss. And today, we're going to go through a few areas of importance as it relates to ADVM-022. First of all, we'll have Dr. Kiss go through the preclinical data, but also he will cover the unmet need for wet AMD. And then we're going to have Dr. Boyer, who

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot